

Development of novel small molecule anticancer drugs targeting USP1

HYUNDAI PHARM



ONCOLOGY	Candidate
Product Type	Small molecules
Indication	BRCA1/2 mutant cancer
Target	USP1
MoA(Mechanism of Action)	Cancer cell death induced by suppression of DNA damage repair by regulating the ubiquitination status
Competitiveness	<ul style="list-style-type: none"> • HD USP1 inhibitors have demonstrated robust target engagement by modulating the pharmacodynamic marker Ub-PCNA (monoubiquitinated Proliferating Cell Nuclear Antigen). • HD USP1 inhibitors demonstrate anti-tumor activity both <i>in vitro</i> and <i>in vivo</i> when combined with PARP inhibitors. • Additive effect with PARP inhibitors in PARP inhibitor-resistant cell lines.
Development Stage	Candidate
Route of Administration	Oral administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.